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Abstract Plipastatins A and B are antifungal antibiotics
belonging to a family of lipopeptides capable of inhibiting
phospholipase A2 (PLA2) and are biosynthesised under certain
circumstances by Bacillus subtilis. U-15N plipastatins A and B
were obtained from cultures of the strain NCIB 8872 on a Landy
medium modified for stable-isotope labelling by the substitution
of the L-glutamic acid used as the sole nitrogen source, by
15NH4Cl. These two lipo-decapeptides, lactonised by esterifica-
tion of the Ile10 C-terminus with the phenolic hydroxyl of Tyr3,
differ only by a D-Ala (plipastatin A)/D-Val (plipastatin B)
substitution at the position 6. The 1H- and 15N-nuclear magnetic
resonance (NMR) signals of a 4:6 mixture of plipastatins A and
B were unambiguously assigned and their structures in dimethyl-
sulfoxide solution were calculated on the basis of a set of NMR-
derived restraints. Plipastatins A and B are well-defined
structures in solution stabilised by a type 1 L-turn comprising
residues 6^9 and several other specific hydrogen bonds. The
structures afford a first molecular basis for the future studies of
their biological activities both in lipidic layers or on
PLA2. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Bacillus subtilis strains produce di¡erent secondary metab-
olites in the form of lipopeptides that have speci¢c activities
against fungi [1], bacteria [2], erythrocytes [3] and di¡erent
yeasts [4]. As a consequence, these metabolites are of a high
value for biotechnological and pharmaceutical applications.
In addition to surfactins, a powerful amphiphilic and surfac-
tant lipopeptide [5], each of these strains speci¢cally produce
only one member of the iturinic family comprising bacillomy-
cins, iturins and mycosubtilin (for a review, see [6]) (Fig. 1).
However, it was observed, by modifying the culture condi-
tions (nitrogen source, pH), that this bacteria may also pro-
duce other compounds as fengycins [7] or plipastatins [8].
These features suggest a high degree of adaptability, by mod-
ulation of the genetic expression in the region of the B. subtilis
genome involved in the synthesis of these two families of
compounds [9].
All these antibiotics are either cyclopeptides (iturinics) or
macrolactones (surfactins, fengycins and plipastatins) charac-
terised by the presence of L and D amino acids and variable
hydrophobic tails [10] (Fig. 1). Iturinics share a common
mechanism of action by inserting into the cytoplasmic mem-
brane by their hydrophobic tail and auto-aggregate to form a
pore which causes the cellular leakage [11]. The plipastatins,
which were isolated from B. subtilis [12,13] and Bacillus cereus
[8], are very similar to fengycins. Their antimicrobial spectrum
remains mainly unknown but it was shown to inhibit the
phospholipase A2 (PLA2) [8], an enzyme involved in a number
of physiologically important cellular processes such as in£am-
mation, acute hypersensitivity and blood platelet aggregation
[14,15]. As for the other lipopeptides produced by B. subtilis,
plipastatins are biosynthesised as a mixture of isoforms char-
acterised by variations in both the nature of the hydrophobic
tail and the amino acid composition [16]. The hydrophobic
tail is a 3(R)-hydroxy hexadecanoic acid (plipastatins A1 and
B1) or a 14(S)-methyl-3(R)-hydroxy hexadecanoic acid (pli-
pastatins A2 and B2) while the amino acid sequence di¡er
in position 6 with a D-Ala (plipastatin A1 and A2) substituted
by a D-Val (plipastatin B1 at B2). Surprisingly, while attempt-
ing to adapt a speci¢c medium of culture for B. subtilis NCIB
8872 by substitution of the nitrogen source (L-GluC15NH4Cl)
for isotope labelling of bacillomycin L [17], we have obtained
two isoforms of plipastatins, plipastatin A and plipastatin B
instead of bacillomycin L which has not been detected any-
more [18]. We report in this paper the detailed nuclear mag-
netic resonance (NMR) structures of both U-15N plipastatins
A and B in dimethylsulfoxide (DMSO) solution obtained after
two major revisions of the previously reported 1H-NMR as-
signment of plipastatin A [19].
2. Materials and methods
2.1. Antibiotic production
The B. subtilis strain NCIB 8872 was obtained from Dr. J.B. Barr,
Royal Victorial Hospital, Belfast, Northern Ireland. B. subtilis was
grown at 35‡C for 150 h in a Landy medium [20], modi¢ed for the
nitrogen source, containing 20 g of D-glucose, 1.82 g of 15NH4Cl
(Isotec Inc.; instead of glutamic acid), 0.5 g of MgSO4, 0.5 g of
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KCl, 6.8 g of KH2PO4, 1.2 mg of Fe2(SO4)3, 0.4 mg of MnSO4, and
1.6 mg of CuSO4 per liter. The pH was adjusted to 7.7 with 10 N
NaOH before autoclaving (the solution of D-glucose was sterilised
separately) [21,22]. The lipopeptides were then isolated and puri¢ed
as reported before for bacillomycin L [17]. We ¢nally obtained 25 mg
of U-15N plipastatins (A and B in a 4:6 ratio determined by NMR,
see below) for 1 l of culture from the chromatographic fractions
corresponding to the RF of bacillomycin L.
2.2. NMR spectroscopy
This amount was dissolved under dry argon in 550 Wl (ca 3.6 mM
total concentration) of DMSO-d6 (CEA-Eurisotop, the solubility in
water is too low). NMR spectra were recorded at 22‡C on a Bruker
Avance DRX 500 spectrometer using a 5 mm (1H, 13C, 15N) triple-
resonance probe head equipped with a supplementary self shielded
z-gradient coil. Spectra were processed using Bruker XWINNMR or
GIFA V.4 [23] software. Double quantum ¢ltered correlation spec-
troscopy [24], total correlation spectroscopy (TOCSY) (Hartmann^
Hann spectroscopy) [25,26] and nuclear Overhauser enhancement
spectroscopy (NOESY) [27,28] experiments were recorded with a
1.5 s recovery delay in the phase-sensitive mode using the States-
TPPI method [29] as data matrices of 512 real (t1)U1024 (t2) complex
data points with accumulation of 32 scans per t1 increment. Mixing
times of 80 ms were used for TOCSY and 350 ms for the NOESY
spectra. The spectral width in both dimensions was 5734 Hz. The data
were apodised with shifted sine-bell and Gaussian window functions
in both F1 and F2 dimensions after zero-¢lling in the t1 dimension to
obtain a ¢nal matrix of 1024 (F1) realU1024 (F2) complex data
points. Proton chemical shifts were referenced to the solvent chemical
shift (D(1H) = 2.49 ppm). Phase-sensitive 15N-heteronuclear single
quantum coherence (HSQC) [30] were recorded with a 1.5 s recovery
delay using the echo^antiecho method [31]. The coherence pathway
selection was achieved by applying pulsed-¢eld gradients as coher-
ence-¢lters [32,33]. The FID was collected as a data matrix of 512
(t1, 15N)U1024 (t2, 1H) complex data points accumulations and 32
scans per t1 increment. Spectral widths were 3005 Hz in F2 and
1773 Hz in F1 with carrier frequencies at 8.5 and 117.0 ppm, respec-
tively.
2.3. Structure calculations
Interproton-distance restraints were derived from two-dimensional
homonuclear NOESY experiments and classi¢ed into three categories.
Upper bounds were ¢xed at 2.7, 3.3 and 5.0 Aî for strong, medium and
weak correlations, respectively. 0.3 Aî were added to NOEs involving
amide protons. The intensity of the NOE between the two HO(NH2)
of Gln8 was considered as a reference intensity for strong corrections.
Pseudo atom correlations [34] of the upper bounds were applied for
distance restraints involving the aromatic protons of Tyr (+2 Aî ) and
unresolved methyl or methylene protons (+1 Aî ). For non-stereospe-
ci¢cally assigned but spectroscopically-resolved diastereotopic pro-
tons, the interproton distances were treated as single (Gr36f)31=6 aver-
age distances. Dihedral angle restraints of M1 were deduced from the
stereospeci¢c assignments of diastereotopic L-protons ( þ 40‡ from the
ideal staggered conformation) [35,36].
Structures were calculated as previously described [17] using the
X-PLOR software version 3.851 [37]. The non-standard (hydrophobic
tail and Orn2) and modi¢ed residues (Allo^Thr4 and ester bond be-
tween Tyr3 and Ile10) were constructed from the X-PLOR libraries
(given as supplementary material). The ester bond between the resi-
dues Tyr3 and Ile10 was maintained plane by de¢nition of suitable
improper-angle restraints. Starting from fully randomised coordinates,
the sampling of the conformational space was performed following a
simulated annealing (SA) protocol (random SA) proposed by Nilges
et al. [38]. For this calculation, the allhdg.pro force ¢eld of X-PLOR
was used. In a second stage of the calculation, random SA structures
with good experimental and geometric energies were further re¢ned
using the full CHARMM22 force-¢eld of X-PLOR. An approximate
solvent electrostatic screening e¡ect was introduced by using a dis-
tance-dependent dielectric constant and by reducing the electric
charges of the formally charged amino acid side chains (Glu1, Glu5
and Orn2) to 20% of their nominal charges de¢ned in the
CHARMM22 force ¢eld. The structures were statistically analysed
using X-PLOR routines and the MOLMOL program [39].
3. Results and discussion
3.1. Resonance assignments of the two plipastatin isoforms
The distinction between the two lipopeptides fengycin and
plipastatin, which di¡er only in the stereochemistry of the Tyr
residues (L to D diastereoisomers, Fig. 1), is possible only by
comparison of their respective 1H chemical shifts in DMSO
that were already reported [7,19]. On this basis, plipastatins A
and B were unambiguously identi¢ed and their spin systems
were easily assigned [34] (Table 1). The greatest chemical shift
di¡erence between the two isoforms concerns the HK of the
residue 6 (Ala or Val). The assignment of Pro7 was straight-
forward with strong dLN and no dKK between Ala6/Val6 and
Pro7, indicating that the peptide bond is in a trans conforma-
tion. Two important discrepancies appeared relative to the
previous spectral assignments of plipastatin A1 [19]. In this
work, the two broad resonances at N= 10.47 and 10.67 ppm
were assigned to the two COOH protons of Glu1 and Glu5.
The HSQC 15N spectrum (Fig. 2) revealed two 1H^15N cross-
peaks for the same 1H chemical shifts that precluded any
COOH proton assignments for these two resonances. We
used the unique Ala6/Val6 and Ile10 spin systems as starting
points for the sequential assignments of the two isoforms. The
sequence-speci¢c assignment proceeded unambiguously and
the two broad resonances at N= 10.51 and 10.72 ppm corre-
sponds to HN protons of Orn2 and Glu5, respectively. Due to
the broad resonance of Orn2 and Glu5 HN, only weak
Fig. 1. Peptide sequences of the major antibiotics produced by B. subtilis. The hydrophobic tail (HT), is constituted of 11 C to 13 C with nor-
mal, iso or anteiso termini. Orn, ornithine; AThr, Allo-Threonine. For fengycins and plipastatins only, the carboxyl group of the Ile10 C-termi-
nus is lactonised with the phenolic hydroxyl of Tyr3 to form a macrolactone ring. X = D-Ala and D-Val for isoforms A and B, respectively.
FEBS 24285 13-11-00
L. Volpon et al./FEBS Letters 485 (2000) 76^80 77
TOCSY transfers were observed from the HN to the HK and
HL.
3.2. NMR restraints and structure calculations of plipastatin A
A total of 125 (28 intra-residue, 64 sequential (i, i+1) and
33 medium-range (i, i+n, 29 n9 4) structurally relevant dis-
tance restraints were used for the structure calculation of pli-
pastatin A and B. In addition, ¢ve M1 angle restraints were
introduced in the restraint set. From the 40 initial structures
calculated using consecutively the force ¢elds allhdg.pro and
Fig. 2. 1H (F2)^15N (F1) HSQC spectrum of plipastatins recorded at 295 K. The cross-peaks labelled with an asterisk correspond to non-identi-
¢ed impurities.
Fig. 3. A: Stereoviews of the 19 NMR structures of plipastatin A (peptidic (N, CK, C) backbone and Tyr3 side chain heavy atoms) superim-
posed for a minimum root mean square deviation (rmsd) using the (N, CK, C and CL, CQ, CN, CO, CR, OR of Tyr3) atoms from residue Tyr3
to Ile10, the P1 family of conformers (see the text) is represented with grey lines and the P2 family with black lines. Amino acids are labelled
according to the amino acid sequence. B: Stereoviews of the closest structure to the geometric average for the P2 family (all-atom representa-
tion). The hydrophobic tail is not represented.
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CHARMM22 of X-PLOR, 19 were retained due to their low
experimental and non-experimental potential energies. The
statistics of the ¢nal structures are given in Table 2.
3.3. Structural analysis of plipastatin A and B
Fig. 3 shows the ensemble of the 19 ¢nal NMR structures
of plipastatin A. This ensemble contains clearly two groups of
conformers which include 7 (P1 family) and 12 (P2 family)
structures, mainly characterised by the two opposite spatial
positions of the ester group between Tyr3 and Ile10. This
alternative induced only a local perturbation of the P dihedral
angle of Glu5 (from 360‡ for P2 to 3120‡ for P1). The rest of
the main chain is very close in the two families of conformers.
Based on the analysis of the P and i angles [40], a type I L-
turn was systematically identi¢ed for residues Ala6 to Tyr9 in
both P1 and P2 families. The L I-turn involves a hydrogen
bond between HN of Tyr9 and CO of Ala6. Other hydrogen
bonds stabilise the models : 6HN^9CO, 8HN^4CO (only for
the P2 family) and 4HO^3CO. Hydrogen bonds 6HN^9CO
and 9HN^6CO were previously proposed for plipastatin A1
and match the observed temperature dependence of the HN
chemical shifts in DMSO [19]. Moreover, the OO atom of
Glu5 is hydrogen bound to the HN protons of both Orn2
and Glu5 in 19 and 14 models, respectively. Such interactions,
together with the vicinity of the large ring-current e¡ects of
Tyr3, could explain the down¢eld chemical shifts observed for
the HN protons of these two residues (Fig. 2). The same phe-
nomenon was observed by NMR for instance in PLA2 [41],
chymotrypsin [42], triosephosphate isomerase [43] for amide
protons involved in strong hydrogen bonds. The HN resonan-
ces of Orn2, Tyr3, and Glu5 are additionally quite broad.
These broad lines could possibly originate from a dynamic
averaging at intermediate frequencies between conformers
with lifetimes in the 20^200 Ws range.
The solution structure of plipastatin B with a D-Val replac-
ing the D-Ala6 does not di¡er from plipastatin A due to the
solvent exposure of the side chain of D-Ala6 (Fig. 3) that can
in consequence accommodate easily a larger side chain of a
valine without conformational changes. The well-de¢ned
structures of plipastatins A and B in DMSO solution will
help, in the future, the understanding of both their behaviour
Table 2
Structural statistics of plipastatin A
Backbone atomsa Heavy atoms
Cartesian coordinate rmsd (Aî ) versus the average geometric structure
All (without the fatty chain) 0.59 ( þ 0.25) 0.79 ( þ 0.36)
3^10 0.59 ( þ 0.24) 0.64 ( þ 0.33)
X-PLOR ^ allhdg.pro X-PLOR ^ CHARMM22
Potential energiesb (kcal mol31) calculated from X-PLOR
Ftotal 14.51 ( þ 1.33) 372.48 ( þ 14.29)
Fbond 0.31 ( þ 0.13) 6.60 ( þ 0.30)
Fangle 11.50 ( þ 0.31) 24.21 ( þ 1.37)
Fimpr 2.40 ( þ 0.45) 1.33 ( þ 0.53)
FCoulombic ^ 3152.60 ( þ 10.55)
FLÿJ 0.08 ( þ 0.09) 38.06 ( þ 4.77)
Fnoe 0.22 ( þ 0.35) 0.36 ( þ 0.17)
NOE violations (as average number per structure)
violationss 0.1 Aî 0.1 0.1
violationss 0.2 Aî 0.0 0.0
armsd are calculated for backbone heavy atoms (C, N, CK of amino acids and CL, CQ, CN, CO, CR, OR of Tyr3).
bFbond is the bond-length deviation energy; Fangle is the valence angles deviation energy; Fimpr deviation energy for the improper angles used to
maintain the planarity of certain groups of atoms; FCoulombic is the Coulombic energy contribution to Ftotal ; FLÿJ is the Lennard^Jones van der
Waals energy function (in the case of the allhdg.pro force ¢eld, only the repulsion term is given); Fnoe is the experimental NOE function calcu-
lated using a force constant of 25 kcal mol31 Aî 32 in the case of the CHARMM22 force ¢eld.
Table 1
1H- and 15N-NMR resonance assignments (ppm) of plipastatins A and B in DMSO solution at 295 K
Residue HN N HK HL Others
Glu1 7.92 121.9 4.52 1.84, 1.96* HQ : 2.13
Orn2 10.54 120.9 4.12 1.76, 1.87 HQ : 1.64; HN : 2.68
Tyr3 8.75 110.7 4.74 2.37*, 3.27 HN : 6.88; HO : 6.83
AThr4 6.82 111.1 4.27 3.68 HQ : 0.96
Glu5 10.73 (10.71) 126.5 (126.5) 3.29 (3.33) 2.02, 2.37 HQ : 1.54, 1.59
Ala6 (Val6) 8.40 (8.33) 123.4 (120.3) 4.98 (4.50) 1.22 (2.06) (HQ,QP : 0.87)
Pro7 4.19 (4.23) 1.93, 2.20 HQ : 1.83, 2.05; HN : 3.51, 3.97
Gln8 7.58 (7.46) 107.6 (107.8) 4.27 1.38, 2.38* (1.37, 2.39) HQ : 2.09, 2.30; NH2 : 6.70, 7.18 N: 108.6
Tyr9 7.49 (7.53) 116.5 4.56 (4.57) 2.91 (2.92) HN : 7.07; HO : 6.63
Ile10 8.99 (8.98) 123.7 (123.8) 3.98 2.00 (1.75) H Q CH3 : 0:91 0:86; H Q CH2 : 1:16 HN : 0:75
Fatty acid H2 H3 H4 H5^H15 methyl groups
2.23 3.72 1.12, 1.28 1.05 0.85, 0.89
An asterisk indicates the HL2 proton when the L methylene protons were stereospeci¢cally assigned. The numbers in parentheses correspond to
the value for plipastatin B. Chemical shifts are given þ 0.01 ppm for 1H and þ 0.05 ppm for 15N.
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once inserted in lipidic layers, or how plipastatins can inhibit
the PLA2 activity.
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